(E)-Methyl 3-(pyriMidin-5-yl)acrylate
- $300.84 - $990
- Product name: (E)-Methyl 3-(pyriMidin-5-yl)acrylate
- CAS: 866621-24-1
- MF: C8H8N2O2
- MW: 164.16
- EINECS:
- MDL Number:MFCD08166596
- Synonyms:2-PROPENOIC ACID, 3-(5-PYRIMIDINYL)-, METHYL ESTER, (2E)-;Methyl (2e)-3-(pyrimidin-5-yl)prop-2-enoate
4 prices
Selected condition:
Brand
- Alichem
- SynQuest Laboratories
- TRC
Package
- 500mg
- 1g
- 5g
- 10g
- ManufacturerAlichem
- Product number866621241
- Product description(E)-Methyl3-(pyrimidin-5-yl)acrylate
- Packaging1g
- Price$300.84
- Updated2021-12-16
- Buy
- ManufacturerAlichem
- Product number866621241
- Product description(E)-Methyl3-(pyrimidin-5-yl)acrylate
- Packaging5g
- Price$877.68
- Updated2021-12-16
- Buy
- ManufacturerSynQuest Laboratories
- Product number4H23-1-28
- Product descriptionMethyl 3-(pyrimidin-5-yl)acrylate 95%
- Packaging10g
- Price$990
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberE521618
- Product description(E)-methyl3-(pyrimidin-5-yl)acrylate
- Packaging500mg
- Price$310
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Alichem | 866621241 | (E)-Methyl3-(pyrimidin-5-yl)acrylate | 1g | $300.84 | 2021-12-16 | Buy |
Alichem | 866621241 | (E)-Methyl3-(pyrimidin-5-yl)acrylate | 5g | $877.68 | 2021-12-16 | Buy |
SynQuest Laboratories | 4H23-1-28 | Methyl 3-(pyrimidin-5-yl)acrylate 95% | 10g | $990 | 2021-12-16 | Buy |
TRC | E521618 | (E)-methyl3-(pyrimidin-5-yl)acrylate | 500mg | $310 | 2021-12-16 | Buy |
Properties
Boiling point :290.2±15.0 °C(Predicted)
Density :1.199±0.06 g/cm3(Predicted)
pka :1.70±0.10(Predicted)
Density :1.199±0.06 g/cm3(Predicted)
pka :1.70±0.10(Predicted)
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|